GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Stevanato Group SPA (NYSE:STVN) » Definitions » Price-to-Owner-Earnings

Stevanato Group SPA (Stevanato Group SPA) Price-to-Owner-Earnings : (As of May. 17, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Stevanato Group SPA Price-to-Owner-Earnings?

As of today (2024-05-17), Stevanato Group SPA's share price is $20.71. Stevanato Group SPA does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Stevanato Group SPA's Price-to-Owner-Earnings or its related term are showing as below:


STVN's Price-to-Owner-Earnings is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 33.96
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-17), Stevanato Group SPA's share price is $20.71. Stevanato Group SPA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $0.55. Therefore, Stevanato Group SPA's PE Ratio for today is 37.59.

As of today (2024-05-17), Stevanato Group SPA's share price is $20.71. Stevanato Group SPA's EPS without NRI for the trailing twelve months (TTM) ended in was $0.57. Therefore, Stevanato Group SPA's PE Ratio without NRI for today is 36.46.

During the past 6 years, Stevanato Group SPA's highest PE Ratio without NRI was 55.33. The lowest was 26.48. And the median was 41.92.


Stevanato Group SPA Price-to-Owner-Earnings Historical Data

The historical data trend for Stevanato Group SPA's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stevanato Group SPA Price-to-Owner-Earnings Chart

Stevanato Group SPA Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - - -

Stevanato Group SPA Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Stevanato Group SPA's Price-to-Owner-Earnings

For the Medical Instruments & Supplies subindustry, Stevanato Group SPA's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Stevanato Group SPA's Price-to-Owner-Earnings Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Stevanato Group SPA's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Stevanato Group SPA's Price-to-Owner-Earnings falls into.



Stevanato Group SPA Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Stevanato Group SPA's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=20.71/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Stevanato Group SPA  (NYSE:STVN) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Stevanato Group SPA Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Stevanato Group SPA's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Stevanato Group SPA (Stevanato Group SPA) Business Description

Traded in Other Exchanges
Address
Via Molinella 17, Piombino Dese, Padua, ITA, 35017
Stevanato Group SPA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. Stevanato's revenue is geographically diversified, with 60% of sales from Europe, the Middle East and Africa (EMEA), 27% in North America, 10% in Asia-Pacific (APAC), and 3% from South America. It has two segments Biopharmaceutical and Diagnostic Solutions and Engineering.